{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:57:41Z","timestamp":1792519061227,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijgc.2025.101966","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:30:12Z","timestamp":1748737812000},"page":"101966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reproducibility of positive AGO score in predicting complete cytoreduction in recurrent low-grade ovarian cancers"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-548X","authenticated-orcid":false,"given":"Emel","family":"Canaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I.","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Kulbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5373-3991","authenticated-orcid":false,"given":"Eser","family":"Ozyurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek P.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijgc.2025.101966_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101966_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101966_bib3","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"issue":"23","key":"10.1016\/j.ijgc.2025.101966_bib4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101966_bib5","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101966_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101966_bib8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101966_bib9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2012.05.007","article-title":"Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience","volume":"126","author":"Mangili","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101966_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2007.02.016","article-title":"Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt\/beta-catenin and PI3K\/Pten signaling pathways","volume":"11","author":"Wu","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101966_bib12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/PAS.0000000000001016","article-title":"High-grade endometrioid carcinoma of the ovary: a clinicopathologic study of 30 cases","volume":"42","author":"Assem","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3-4","key":"10.1016\/j.ijgc.2025.101966_bib16","first-page":"129","article-title":"\"IMO\u201d\u2013intraoperative mapping of ovarian cancer","volume":"125","author":"Sehouli","year":"2003","journal-title":"Zentralbl Gynakol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101966_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101966_bib18","first-page":"3423","article-title":"AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer","volume":"35","author":"Muallem","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ijgc.2025.101966_bib19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2147\/OTT.S67812","article-title":"A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology","volume":"7","author":"Chen","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"1095","key":"10.1016\/j.ijgc.2025.101966_bib20","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180571","article-title":"Low-grade epithelial ovarian cancer: what a radiologist should know","volume":"92","author":"Elsherif","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijgc.2025.101966_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejro.2015.01.001","article-title":"CT features of low grade serous carcinoma of the ovary","volume":"2","author":"Pannu","year":"2015","journal-title":"Eur J Radiol Open"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101966_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13244-021-01004-7","article-title":"Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists","volume":"12","author":"Amante","year":"2021","journal-title":"Insights Imaging"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101966_bib23","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101966_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101966_bib25","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:09:45Z","timestamp":1751645385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1048891X25010862"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101966","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reproducibility of positive AGO score in predicting complete cytoreduction in recurrent low-grade ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101966"}}